Literature DB >> 12231489

Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease.

Karine Marquis1, Richard Debigaré, Yves Lacasse, Pierre LeBlanc, Jean Jobin, Guy Carrier, François Maltais.   

Abstract

This study was undertaken to test the hypothesis that a reduction in midthigh muscle cross-sectional area obtained by CT scan (MTCSA(CT)) is a better predictor of mortality in chronic obstructive pulmonary disease (COPD) than low body mass index (BMI). We also wished to evaluate whether anthropometric measurements could be used to estimate MTCSA(CT). One hundred forty-two patients with COPD (age = 65 +/- 9 years, mean +/- SD, 26 F, BMI = 26 +/- 6 kg/m(2), FEV(1) = 42 +/- 16% predicted) were recruited from September 1995 to April 2000 with a mean follow-up of 41 +/- 18 months. The primary end-point was all-cause mortality during the study period. A Cox proportional hazards regression model was used to predict mortality using the following independent variables: age, sex, daily use of corticosteroid, FEV(1), DL(CO), BMI, thigh circumference, MTCSA(CT), peak exercise workrate, Pa(O2), and Pa(CO2). Only MTCSA(CT) and FEV(1) were found to be significant predictors of mortality (p = 0.0008 and p = 0.01, respectively). A second analysis was also performed with FEV(1) and MTCSA(CT) dichotomized. Patients were divided into four subgroups based on FEV(1) (< or >or= 50% predicted) and MTCSA(CT) (< or >or= 70 cm(2)). Compared with patients with an FEV(1) >or= 50% predicted and a MTCSA(CT) >or= 70 cm(2), those with an FEV(1) < 50% predicted and a MTCSA(CT) >or= 70 cm(2) had a mortality odds ratio of 3.37 (95% confidence interval, 0.41-28.00), whereas patients with an FEV(1) < 50% predicted and a MTCSA(CT) < 70 cm(2) had a mortality odds ratio of 13.16 (95% confidence interval, 1.74-99.20). MTCSA(CT) could not be estimated with sufficient accuracy from anthropometric measurements. In summary, we found in this cohort of patients with COPD that (1) MTCSA(CT) was a better predictor of mortality than BMI, and (2) MTCSA had a strong impact on mortality in patients with an FEV(1) < 50% predicted. These findings suggest that the assessment of body composition may be useful in the clinical evaluation of these patients.

Entities:  

Mesh:

Year:  2002        PMID: 12231489     DOI: 10.1164/rccm.2107031

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  218 in total

1.  Resveratrol reverses monocrotaline-induced pulmonary vascular and cardiac dysfunction: a potential role for atrogin-1 in smooth muscle.

Authors:  Michael L Paffett; Selita N Lucas; Matthew J Campen
Journal:  Vascul Pharmacol       Date:  2011-11-25       Impact factor: 5.773

Review 2.  The effect of obesity on chronic respiratory diseases: pathophysiology and therapeutic strategies.

Authors:  Magali Poulain; Mariève Doucet; Geneviève C Major; Vicky Drapeau; Frédéric Sériès; Louis-Philippe Boulet; Angelo Tremblay; François Maltais
Journal:  CMAJ       Date:  2006-04-25       Impact factor: 8.262

Review 3.  Models of accelerated sarcopenia: critical pieces for solving the puzzle of age-related muscle atrophy.

Authors:  Thomas W Buford; Stephen D Anton; Andrew R Judge; Emanuele Marzetti; Stephanie E Wohlgemuth; Christy S Carter; Christiaan Leeuwenburgh; Marco Pahor; Todd M Manini
Journal:  Ageing Res Rev       Date:  2010-05-14       Impact factor: 10.895

4.  Joy's index.

Authors: 
Journal:  Clin Med (Lond)       Date:  2010-10       Impact factor: 2.659

Review 5.  Metabolism and Skeletal Muscle Homeostasis in Lung Disease.

Authors:  Ermelinda Ceco; Samuel E Weinberg; Navdeep S Chandel; Jacob I Sznajder
Journal:  Am J Respir Cell Mol Biol       Date:  2017-07       Impact factor: 6.914

Review 6.  Selecting lung transplant candidates: where do current guidelines fall short?

Authors:  Jaime L Hook; David J Lederer
Journal:  Expert Rev Respir Med       Date:  2012-02       Impact factor: 3.772

7.  Altered tissue distribution in adults with cystic fibrosis.

Authors:  C E Bolton; A A Ionescu; W D Evans; R J Pettit; D J Shale
Journal:  Thorax       Date:  2003-10       Impact factor: 9.139

8.  Skeletal Muscle Dysfunction in Chronic Obstructive Pulmonary Disease. What We Know and Can Do for Our Patients.

Authors:  Ariel Jaitovich; Esther Barreiro
Journal:  Am J Respir Crit Care Med       Date:  2018-07-15       Impact factor: 21.405

Review 9.  Palliative care in chronic obstructive pulmonary disease: a review for clinicians.

Authors:  David A Seamark; Clare J Seamark; David M G Halpin
Journal:  J R Soc Med       Date:  2007-05       Impact factor: 5.344

Review 10.  Nutritional aspects of chronic obstructive pulmonary disease.

Authors:  Daniel A King; Francis Cordova; Steven M Scharf
Journal:  Proc Am Thorac Soc       Date:  2008-05-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.